Drug Trial Radar · NCT06241313
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,158
Actual
Start
Mar 25, 2024
Primary completion
Jul 7, 2025
Study completion Aug 11, 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Feb 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A migraine attack is a moderate or severe headache that usually occurs on one side of the head and is often accompanied by throbbing, sensitivity to light, sensitivity to sound, nausea, or other symptoms. The main goal of the study is to see if atogepant is effective, safe, and well-tolerated in treating migraine attacks quickly. Atogepant is a medicine currently approved for the preventive treatment of migraine in adults and has been shown to be effective and well tolerated when taken daily to prevent migraine attacks. This study includes double-blind phase means that neither the participants nor the study doctors know who is given which study treatment (atogepant or placebo) followed by an open-label phase meaning that both participants and study doctors know which study treatment is given. All participants will receive atogepant during the open-label part of the study. This study will include 1300 participants aged 18-75 years with a history of migraine at approximately 160 sites across the world. All participants will receive both atogepant and placebo to treat qualifying migraines. At the start of the study, participants will be randomized to 1 of 4 dosing sequences to determine when they will receive atogepant and when they will receive placebo during the study. After treating 4 qualifying migraine attacks, participants will receive open-label atogepant for any additional migraine attacks they have until the end of the study (Week 24). There may be a bigger responsibility for participants in this study than there would be in participants receiving standard of care treatment. participants will attend regular visits during the study at a hospital or clinic, as well as telephone visits, and the effects of treatment will be checked by completion of questionnaires in an electronic diary, medical assessments, blood tests, and checking for side effects.
Conditions
- Migraine
Interventions
AtogepantDrug
Oral Tablet
Placebo for AtogepantDrug
Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Pain Freedom at 2 Hours After the Double-Blind (DB) Dose for the First AttackTime frame: Approximately 16 Weeks
Locations
149 sites in 15 countries. Site status is shown where the registry gives one.
AZ Groeninge /ID# 257586
Kortrijk, Belgium
CHR de la Citadelle /ID# 257587
Liège, Belgium
H.-Hartziekenhuis Lier /ID# 257577
Lier, Belgium
Universitair Ziekenhuis Antwerpen /ID# 257582
Edegem, Antwerpen, Belgium
Universitair Ziekenhuis Brussel /ID# 257584
Jette, Brussels Capital, Belgium
Cabinet Prive Dr Sava /ID# 257581
Saint-Nicolas, Liege, Belgium
Jessa Ziekenhuis /ID# 257578
Hasselt, Limburg, Belgium
Algemeen Ziekenhuis Sint-Jan Brugge /ID# 257585
Bruges, West-Vlaanderen, Belgium
Baotou Central Hospital /ID# 258786
Baotou, China
The first people's Hospital Affiliated to Shanghai Jiaotong University /ID# 259554
Shanghai, China
The first affiliated hospital of bengbu medical college /ID# 258758
Bengbu, Anhui, China
Beijing Friendship Hospital /ID# 258830
Beijing, Beijing Municipality, China
Xuanwu Hospital Capital Medical University /ID# 258510
Beijing, Beijing Municipality, China
Peking University Third Hospital /ID# 259573
Beijing, Beijing Municipality, China
Chinese PLA General Hospital /ID# 257540
Beijing, Beijing Municipality, China
Peking University First Hospital /ID# 258672
Xicheng District, Beijing Municipality, China
Fujian Medical University Union Hospital /ID# 259575
Fuzhou, Fujian, China
The First Affiliated Hospital of Xiamen University /ID# 259576
Xiamen, Fujian, China
Lanzhou University Second Hospital /ID# 259667
Lanzhou, Gansu, China
Guangzhou First People's Hospital /ID# 258656
Guangzhou, Guangdong, China
The Second Affiliated Hospital of Guangzhou Medical University /ID# 258638
Guangzhou, Guangdong, China
The University Of Hong Kong - Shenzhen Hospital /ID# 258462
Shenzhen, Guangdong, China
The Affiliated Hospital of Guizhou Medical University /ID# 259536
Guiyang, Guizhou, China
Hainan General Hospital /ID# 259548
Haikou, Hainan, China
Hebei General Hospital /ID# 258583
Shijiazhuang, Hebei, China
Zhengzhou People's Hospital /ID# 258670
Zhengzhou, Henan, China
The Second Xiangya Hospital Of Central South University /ID# 260623
Changsha, Hunan, China
The Third Xiangya Hospital of Central South University /ID# 258787
Changsha, Hunan, China
Zhuzhou Central Hospital /ID# 260076
Zhuzhou, Hunan, China
The Second Affiliated Hospital of Nanjing Medical University /ID# 258648
Nanjing, Jiangsu, China
The Second Affiliated Hospital of Soochow University /ID# 259551
Suzhou, Jiangsu, China
The First Affiliated Hospital of Soochow University /ID# 258783
Suzhou, Jiangsu, China
Jiangxi Pingxiang Peoples Hospital /ID# 258652
Pingxiang, Jiangxi, China
The First Hospital of Jilin University /ID# 259585
Changchun, Jilin, China
The Second hospital of Jilin university /ID# 258556
Changchun, Jilin, China
General Hospital of Northern Theater Command /ID# 259556
Shenyang, Liaoning, China
Shaanxi Provincial PeopleS Hospital /ID# 259529
Xi'an, Shaanxi, China
Second Hospital of Shanxi Medical University /ID# 259669
Taiyuan, Shanxi, China
West China Hospital, Sichuan University /ID# 258664
Chengdu, Sichuan, China
Tianjin Medical University General Hospital /ID# 259513
Tianjin, Tianjin Municipality, China
Showing 40 of 149 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.